The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Open accessAbstract
BACKGROUND: The amyloid fibril deposits that cause systemic amyloidosis always contain the nonfibrillar normal plasma protein, serum amyloid P component (SAP). The drug (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) efficiently depletes SAP from the plasma but leaves some SAP in amyloid deposits that can be specifically targeted by therapeutic IgG anti-SAP antibodies. In murine amyloid A type amyloidosis, the binding of these antibodies to the residual SAP in amyloid deposits activates complement and triggers the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. METHODS: We conducted an open-label, single-dose-escalation, phase 1 trial involving 15 patients with systemic amyloidosis. After first using CPHPC to deplete circulating SAP, we infused a fully humanized monoclonal IgG1 anti-SAP antibody. Patients with clinical evidence of cardiac involvement were not included for safety reasons. Organ function, inflammatory markers, and amyloid load were monitored. RESULTS: There were no serious adverse events. Infusion reactions occurred in some of the initial recipients of larger doses of antibody; reactions were reduced by slowing the infusion rate for later patients. At 6 weeks, patients who had received a sufficient dose of antibody in relation to their amyloid load had decreased liver stiffness, as measured with the use of transient elastography. These patients also had improvements in liver function in association with a substantial reduction in hepatic amyloid load, as shown by means of SAP scintigraphy and measurement of extracellular volume by magnetic resonance imaging. A reduction in kidney amyloid load and shrinkage of an amyloid-laden lymph node were also observed. CONCLUSIONS: Treatment with CPHPC followed by an anti-SAP antibody safely triggered clearance of amyloid deposits from the liver and some other tissues. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01777243.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Self-citationAmyloid P component. A critical review
Pepys, M. B., Booth, D. R., Hutchinson, W. L., Gallimore, J. R., Collins, I. M., & Hohenester, E. (1997) · Amyloid · doi:10.3109/13506129709003838 · Cited by 181
Self-citationTarget Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis
Sahota, T., Berges, A., Barton, S., Cookson, L., Zamuner, S., & Richards, D. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.15 · Cited by 19
Self-citation
Cited by
Messroghli, D. R., Moon, J. C., Ferreira, V. M., Grosse-Wortmann, L., He, T., Kellman, P., Mascherbauer, J., Nezafat, R., Salerno, M., Schelbert, E. B., et al. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-017-0389-8 · Cited by 1,727
Self-citationTransthyretin Amyloid Cardiomyopathy
Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W., & Maurer, M. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.003 · Cited by 1,112
Kittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
AL (Light-Chain) Cardiac Amyloidosis
Falk, R. H., Alexander, K. M., Liao, R., & Dorbala, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.053 · Cited by 649
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citation
Metadata
- Authors
- Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., Fontana, M., Moon, J. C., Pinzani, M., Gillmore, J. D., Hawkins, P. N., & Pepys, M. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-17
- Volume
- 373
- Issue
- 12
- Pages
- 1106-1114
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282508430
- Cited by
- 378
- References
- 3
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. https://app.cochat.ai/papers/10.1056/nejmoa1504942
- The paper
- Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., Fontana, M., Moon, J. C., Pinzani, M., Gillmore, J. D., Hawkins, P. N., & Pepys, M. B. (2015). Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1504942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.